Astragaloside IV alleviates lung inflammation in Klebsiella pneumonia rats by suppressing TGF-β1/Smad pathway

Astragaloside IV alleviates lung inflammation in Klebsiella pneumonia rats by suppressing TGF-β1/Smad pathway

Astragaloside IV is a biologically active substance derived from the traditional Chinese medicine Astragalus mambranaceus Bunge, and has antioxidant, anti-inflammatory, and anti-apoptotic properties. In this study, we aimed to investigate the effects of astragaloside IV on Klebsiella pneumonia rats...

Full description

Bibliographic Details
Main Authors:	Lei Li, Jie Guan, Rongjun Lin, Fang Wang, Hui Ma, Chenggang Mao, Xingqing Guo, Zhenghai Qu, Renzheng Guan
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2023-07-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	Lung inflammation TGF-β1/Smad pathway Astragaloside IV K. pneumoniae Pharmacology
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2023000100646&tlng=en

Similar Items

Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy
by: Du N, et al.
Published: (2018-10-01)

Research progress of astragaloside IV in the treatment of atopic diseases
by: Shencun Yu, et al.
Published: (2022-12-01)

Network Pharmacology and Experimental Evidence Identify the Mechanism of Astragaloside IV in Oxaliplatin Neurotoxicity
by: Xu J, et al.
Published: (2021-01-01)

Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma
by: Ramesh B. Kasetti, et al.
Published: (2021-11-01)

Astragaloside IV alleviates lipopolysaccharide‐induced preeclampsia‐like phenotypes via suppressing the inflammatory responses
by: Dilihuma Tuerxun, et al.
Published: (2021-03-01)

Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV
by: Zehui Xu, et al.
Published: (2023-12-01)

Astragaloside IV, as a potential anticancer agent
by: Dongqin Xia, et al.
Published: (2023-02-01)

In Silico Prediction of Molecular Targets of Astragaloside IV for Alleviation of COVID-19 Hyperinflammation by Systems Network Pharmacology and Bioinformatic Gene Expression Analysis
by: Chenliang Ge, et al.
Published: (2020-09-01)

Astragaloside-IV Alleviates Heat-Induced Inflammation by Inhibiting Endoplasmic Reticulum Stress and Autophagy
by: Zhiwei Dong, et al.
Published: (2017-06-01)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
by: Lu-Yun Qin, et al.
Published: (2022-03-01)

Astragalosidic Acid: A New Water-Soluble Derivative of Astragaloside IV Prepared Using Remarkably Simple TEMPO-Mediated Oxidation
by: Lin-Sen Qing, et al.
Published: (2017-07-01)

Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function
by: Chuang Sun, et al.
Published: (2021-07-01)

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology
by: Haoran Jing, et al.
Published: (2021-11-01)

Pharmacological Effects of Astragaloside IV: A Review
by: Yutong Liang, et al.
Published: (2023-08-01)

Effect of astragaloside IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress
by: Chunlan Ji, et al.
Published: (2018-09-01)

Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease
by: Mei-Ling Xia, et al.
Published: (2020-04-01)

Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis
by: Yuan S, et al.
Published: (2023-04-01)

Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling
by: Lianlian Tian, et al.
Published: (2021-09-01)

Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice
by: Wang X, et al.
Published: (2018-08-01)

The Effect of Astragaloside IV on Isoproterenol-Induced Myocardial Infarction in Rats
by: Fatemeh Fathizad, et al.
Published: (2019-06-01)

The potential molecular pathways of Astragaloside-IV in colorectal cancer: A systematic review
by: Tang Ziyang, et al.
Published: (2023-11-01)

Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats
by: Feng Zhao, et al.
Published: (2011-05-01)

A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
by: En Hu, et al.
Published: (2023-04-01)

Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
by: Tan YQ, et al.
Published: (2020-09-01)

Astragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis
by: Zhuang Zhuang, et al.
Published: (2019-11-01)

Astragaloside IV Targets Macrophages to Alleviate Renal Ischemia-Reperfusion Injury via the Crosstalk between Hif-1α and NF-κB (p65)/Smad7 Pathways
by: Lumin Tang, et al.
Published: (2022-12-01)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases
by: Chunkun Yang, et al.
Published: (2023-05-01)

The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease
by: Yiwei Gao, et al.
Published: (2023-07-01)

Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases
by: Tan J, et al.
Published: (2023-07-01)

Astragaloside IV-enhanced anti-hepatocarcinoma immunity of dendritic cells
by: Hongxing Guo, et al.
Published: (2022-05-01)

Mechanism of Astragaloside Ⅳ on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation
by: ZHOU Zhipeng, et al.
Published: (2022-07-01)

Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII
by: Wanting Qin, et al.
Published: (2024-02-01)

The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications
by: Li L, et al.
Published: (2023-03-01)

Protective effect of Astragaloside IV against sepsis-induced acute lung injury in rats
by: Ruiqin Huang, et al.
Published: (2016-05-01)

Research Progress on the Ability of Astragaloside IV to Protect the Brain Against Ischemia-Reperfusion Injury
by: Xianhui Kang, et al.
Published: (2021-11-01)

Astragaloside IV promotes angiogenesis by targeting SIRT7/VEGFA signaling pathway to improve brain injury after cerebral infarction in rats
by: Zhijie Ou, et al.
Published: (2023-12-01)

Astragaloside IV Protects Ethanol-Induced Gastric Mucosal Injury by Preventing Mitochondrial Oxidative Stress and the Activation of Mitochondrial Pathway Apoptosis in Rats
by: Shumin Qin, et al.
Published: (2019-08-01)

Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway
by: Ping Gao, et al.
Published: (2021-01-01)

Network pharmacology and in vitro experimental verification to reveal the mechanism of Astragaloside IV against kidney ischemia-reperfusion injury
by: Yan Guo, et al.
Published: (2023-11-01)

Astragaloside IV Alleviates Infarction Induced Cardiomyocyte Injury by Improving Mitochondrial Morphology and Function
by: Wen Zhang, et al.
Published: (2022-02-01)